As I wrote in a late July post titled Alzheimer’s Treatments Undergoing Late-stage Trials, we are now in a crunch time where long studied Alzheimer’s treatment drugs are in late-state testing to see if they actually perform as researchers hoped. Today, news broke that Pfizer’s Bapineuzumab, which failed the first late-stage trial last month, has failed the second trial. According to an article on Businessweek.com, most plans for further testing of the drug by Pfizer-J&J have ended. The company had hoped Bapineuzumab would be first drug on the market to effectively slow or reverse Alzheimer’s disease.
Read more about the failure of the long awaited Bapineuzumab:
Purchase Minding Our Elders: Caregivers Share Their Personal Stories – paperback or ebook
Comments